Source: Eur Respir J 2013; 41: 203-216
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
De Boeck K., Kent L., Davies J., Derichs N., Amaral M., Rowe S.M., Middleton P., de Jonge H., Bronsveld I., Wilschanski M., Melotti P., Danner-Boucher I., Boerner S., Fajac I., Southern K., de Nooijer R.A., Bot A., de Rijke Y., de Wachter E., Leal T., Vermeulen F., Hug M.J., Rault G., Nguyen-Khoa T., Barreto C., Proesmans M., Sermet-Gaudelus I.. CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J 2013; 41: 203-216

Member's Comments

No comment yet.

Related content which might interest you: Atypical cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=38 Year: 2006 Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function Source: Eur Respir J 2011; 37: 1076-1082 Year: 2011 The potential of closed circuit lung clearance index (LCI) to provide longitudinal clinical utility in cystic fibrosis (CF). Source: International Congress 2019 – Physiology of cystic fibrosis Year: 2019 The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications Source: Virtual Congress 2020 – Respiratory infections Year: 2020 Association of residual function of cystic fibrosis transmembrane conductance regulator and lung clearance index in patients with normal FEV1 Source: International Congress 2017 – Assessing the impact of respiratory and sleep problems in children Year: 2017 How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment Source: International Congress 2016 – Closing the gap: novel translational research strategies Year: 2016 A randomized, placebo controlled 4-week study in COPD of QBW251, a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Measuring CFTR function in respiratory epithelial cell cultures: step to individualize treatments in cystic fibrosis? Source: Virtual Congress 2021 – Monitoring of lung disease and CFTR function in children with cystic fibrosis Year: 2021 An assay of CF transmembrane conductance regulator function that uses primary CF intestinal organoids: shared experiences with the Russian CF centre Source: International Congress 2018 – Russian Speaking Programme 2018: Part I Year: 2018 Intestinal current measurement (ICM) as a new diagnostic test for cystic fibrosis (CF) Source: Annual Congress 2011 - Cystic fibrosis: New aspects of diagnosis, inflammation and detecting exacerbation Year: 2011 Cystic fibrosis transmembrane conductance regulator pharmacotherapy Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88 Year: 2006 A borderline, or negative sweat test, leads to a diagnostic delay in hypertrypsinaemic cystic fibrosis (CF) infants with mild CFTR mutations Source: Eur Respir J 2001; 18: Suppl. 33, 124s Year: 2001 Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis Source: Eur Respir J 2011; 37: 59-69 Year: 2011 ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020 Potential difference test is valuable in the diagnosis of cystic fibrosis (CF) Source: Eur Respir J 2004; 24: Suppl. 48, 614s Year: 2004 Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment Year: 2013 Nasal potential difference measurements in patients with atypical cystic fibrosis Source: Eur Respir J 2001; 17: 1208-1215 Year: 2001 Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 The diagnosis of cystic fibrosis by sweat test: the establishment of age specific reference intervals Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID) Source: Breathe, 17 (3) 210088; 10.1183/20734735.0088-2021 Year: 2021